Trial Information

Summary: A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Status: Completed

Protocol Number: NC19794

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: A multi-center, open label, extension study to evaluate the long-term safety and tolerability of GK Activator (2) in type 2 diabetic patients from studies BM18248 or BM18249

Brief Summary: This study will evaluate the long-term safety and tolerability of GK Activator (2) at doses ranging from 25mg - 100mg po bid, administered alone or in combination with metformin, in patients with type 2 diabetes. Eligible patients will be those who have completed study BM18248 (GK Activator (2) monotherapy) or BM18249 (GK Activator (2) and metformin); they will continue on the same treatment regimen (mono or combination therapy) as they received in the initial study. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals. Target sample size is 259.

Study Phase: II

Study Design / Study Details:

• Purpose: Treatment
• Allocation: Randomized
• Masking: Open Label
• Control: Active
• Assignment: Parallel
• Endpoints: Safety/Efficacy

Study Type:

Condition: Diabetes Mellitus, Type 2

Intervention Type: Drug

Intervention Name: GK Activator (2)

Primary Outcome: 1. AEs, laboratory parameters, ECG. Time frame: Throughout study

Key Secondary Outcomes: 1. Mean change from original baseline in HbA1c, FPG, lipid profile. Time frame: Throughout study

Inclusion Criteria:

Exclusion Criteria:

Gender: Males or Females

Age Limits: Min: 30 Years Max: 75 Years

Accepts Healthy Volunteers: No

Trial Registration Date: 05/04/2006

Date Last Updated: 06/17/2008

Link To Trial Results

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:40:47 PM